New immune therapy tested for HPV-Linked throat cancer
NCT ID NCT07172256
Summary
This study is testing a new immune therapy called CUE-101, both alone and combined with an existing drug (pembrolizumab), as a treatment given before surgery for advanced head and neck cancer caused by HPV-16. It will involve about 30 people with newly diagnosed cancer that cannot be easily removed by surgery. The main goal is to see if the treatment is safe and if it boosts the immune system's ability to fight the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yale University
New Haven, Connecticut, 06510, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.